#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	6614	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2157	583.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1654	1654	T	708	T,A,C	436,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	6614	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2157	583.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1388	1388	C	842	C,G	527,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	12874	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3732	633.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1749	1749	A	707	A	452	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	12874	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3732	633.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2383	2383	C	601	C	377	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	12874	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3732	633.4	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3009	3009	T	741	T,C	237,245	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	12874	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3732	633.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2457	2457	A	640	A	400	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	452	folP	855	855	100.0	folP.l15.c4.ctg.1	1736	49.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1017	1019	AGC	71;71;71	A;G;C,G	46;47;46,1	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1480	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3486	81.3	1	SNP	p	S91F	1	.	.	271	273	TTC	583	585	TTC	105;105;105	T;T,G;C,T	67;63,1;64,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1480	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3486	81.3	1	SNP	p	G95N	0	.	.	283	285	GGC	595	597	GGC	116;114;114	G;G;C	74;72;68	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1480	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3486	81.3	1	SNP	p	D95G	1	.	.	283	285	GGC	595	597	GGC	116;114;114	G;G;C	74;72;68	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	388	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1423	55.1	1	SNP	p	G45D	0	.	.	133	135	GGC	417	419	GGC	119;119;119	G;G;C	70;69;71	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	338	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1097	56.1	0	.	n	.	0	A197.	DEL	197	197	A	700	700	A	128	A	76	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1246	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3045	79.0	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1427	1429	GTC	91;91;89	G;T;C	62;62;62	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1246	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3045	79.0	1	SNP	p	D86N	0	.	.	256	258	GAC	533	535	GAC	108;108;113	G;A,C,T;C	71;67,1,1;73	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1246	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3045	79.0	1	SNP	p	R87W	0	.	.	259	261	CGT	536	538	CGT	114;115;116	C,A;G;T,G	74,1;73;74,1	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1246	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3045	79.0	1	SNP	p	S87R	1	.	.	259	261	CGT	536	538	CGT	114;115;116	C,A;G;T,G	74,1;73;74,1	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1246	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3045	79.0	1	SNP	p	R87I	0	.	.	259	261	CGT	536	538	CGT	114;115;116	C,A;G;T,G	74,1;73;74,1	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1246	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3045	79.0	1	SNP	p	S88P	0	.	.	262	264	TCC	539	541	TCC	116;116;116	T,G;C,T;C	77,1;78,1;80	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1064	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3132	64.9	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1619	1621	TGC	78;78;78	T;G;C	53;51;54	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1064	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3132	64.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1829	1831	GGC	65;65;67	G;G;C	44;44;44	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	1252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2146	107.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1127	1129	GCA	157;163;161	G,T,A;C,G;A,C	100,1,1;103,1;102,1	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2146	107.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1130	1132	ATC	161;160;160	A,C;T,C;C,T	101,1;103,1;104,1	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2146	107.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1142	1144	GTG	157;157;157	G;T;G	104;102;103	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2146	107.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1142	1144	GTG	157;157;157	G;T;G	104;102;103	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2146	107.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1646	1648	ACC	87;87;87	A;C;C	57;56;59	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2146	107.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1700	1702	GCG	71;71;71	G;C;G,T	50;45;47,1	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2146	107.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1700	1702	GCG	71;71;71	G;C;G,T	50;45;47,1	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2146	107.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1823	1825	GGC	59;59;59	G;G,T;C,T	41;41,1;41,1	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2146	107.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1832	1834	GGC	51;52;52	G;G;C	37;38;36	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2146	107.3	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1850	1852	TCG	56;55;55	T,G;C,A;G	37,2;38,1;37	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	2454	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3054	142.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1624	1626	CCG	124;125;125	C,G;C;G,C	81,2;86;77,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	642	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1676	70.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	463	463	C	45	C	28	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	810	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1966	76.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	561	563	GAA	139;132;132	G;A;A	89;85;85	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	810	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1966	76.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	849	851	GAT	102;107;107	G;A;T,G	67;67;63,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	810	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1966	76.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	972	974	TCA	118;118;118	T;C,G;A,G	80;80,1;80,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	810	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1966	76.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1101	1103	GTC	105;107;106	G;T,C;C	71;70,1;71	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	810	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1966	76.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1431	1433	GCA	108;104;104	G;C;A,G	69;67;65,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	810	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1966	76.9	1	SNP	p	G120K	1	.	.	358	360	AAG	807	809	AAG	102;104;104	A;A;G,C	67;68;69,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	810	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1966	76.9	1	SNP	p	A121D	1	.	.	361	363	GAC	810	812	GAC	104;104;104	G,T;A;C	68,2;69;71	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	810	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1966	76.9	1	SNP	p	D121N	0	.	.	361	363	GAC	810	812	GAC	104;104;104	G,T;A;C	68,2;69;71	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	783	3376	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5035	126.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1840	1842	AAT	159;158;158	A,T;A;T	103,1;103;102	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	783	3376	rpoB	4179	455	99.6	rpoB.l6.c4.ctg.2	496	3.6	0	.	p	.	0	Q388H	NONSYN	1162	1164	CAA	379	381	CAC	2;2;2	C;A;C,A	1;1;0,1	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	783	3376	rpoB	4179	455	99.6	rpoB.l6.c4.ctg.2	496	3.6	0	.	p	.	0	L389M	NONSYN	1165	1167	TTG	382	384	ATG	2;2;2	A,T;T;G	0,1;1;1	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	783	3376	rpoB	4179	455	99.6	rpoB.l6.c4.ctg.2	496	3.6	0	.	p	.	0	N391K	NONSYN	1171	1173	AAC	388	390	AAA	2;2;2	A;A;A,C	1;1;0,1	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	783	3376	rpoB	4179	455	99.6	rpoB.l6.c4.ctg.2	496	3.6	0	.	p	.	0	F395fs	FSHIFT	1183	1183	T	400	400	T	2	T	1	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	318	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1399	46.6	1	SNP	p	V57M	1	.	.	169	171	ATG	558	560	ATG	120;120;121	A;T;G	76;76;77	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
